SCHEMBL2127754

SCHEMBL2127754

COc1c(C=Cc2ccc(NS(C)(=O)=O)cn2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.78
CRBN Q96SW2 1/20 0.37
FYN P06241 2/20 0.35
TGFBR1 P36897 1/20 0.35
ACVR1 Q04771 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
BRD4 O60885 4/20 0.33
MET P08581 2/20 0.33
PIP4K2A P48426 1/20 0.33
PIP4K2B P78356 1/20 0.33
PIP4K2C Q8TBX8 1/20 0.33
PDPK1 O15530 1/20 0.33
ABL1 P00519 1/20 0.32
EP300 Q09472 1/20 0.32
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543171 1.00 CYP3A4 (0.78) CYP3A4CRBNFYNTGFBR1ACVR1
SCHEMBL2128074 0.88 CYP3A4 (1.00) CYP3A4CRBNBRD4PIP4K2APIP4K2B
SCHEMBL2128077 0.88 CYP3A4 (1.00) CYP3A4CRBNBRD4PIP4K2APIP4K2B
SCHEMBL1542410 0.88 CYP3A4 (0.72) CYP3A4CRBNFYNTGFBR1ACVR1
SCHEMBL2127972 0.88 CYP3A4 (0.72) CYP3A4CRBNFYNTGFBR1ACVR1
SCHEMBL1764335 0.87 CYP3A4 (0.60) CYP3A4CRBNFYNTGFBR1ACVR1
SCHEMBL1764337 0.87 CYP3A4 (0.60) CYP3A4CRBNFYNTGFBR1ACVR1
SCHEMBL2128959 0.87 CYP3A4 (0.71) CYP3A4CRBN
SCHEMBL1542737 0.87 CYP3A4 (0.71) CYP3A4CRBN
SCHEMBL2128476 0.87 CYP3A4 (0.59) CYP3A4CRBNFYNTGFBR1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885CRBN 1397/4885FYN 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.